.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing patients with hereditary cancer syndromes requires precise risk data. Recent research has significantly clarified ATM variant cancer risks, providing clinicians with robust hazard ratios (HR) and cumulative risk estimates. Furthermore, this data is vital for families carrying pathogenic or predicted pathogenic variants (PV/PPV) of the ATM gene, as it informs the timing of life-saving screenings.
Specifically, researchers observed a four-fold increase in the risk of female breast cancer (HR 4.0) within a large cohort of 141 ataxia-telangiectasia families. Consequently, clinicians must prioritize specialized screening for this high-risk group. Additionally, the risk for pancreatic cancer was notably elevated, with hazard ratios of 6.6 for females and 2.8 for males. However, this study noted that these risk patterns remained similar across various family settings.
Regarding cumulative risks, the data provides a clear timeline for intervention. Moreover, for women born between 1960 and 1969, the breast cancer risk reaches 9.9% by age 50 and 40% by age 80. Notably, the lifetime risk of pancreatic cancer by age 80 is approximately 8.1% for females and 5.1% for males. This study showed no statistically significant increase in the risk of ovarian or prostate cancers, focusing clinical attention on the breast and pancreas.
The primary risks involve female breast cancer and pancreatic cancer for both genders. Female heterozygotes face a significantly higher hazard ratio compared to the general population.
According to this specific cohort analysis, there was no statistically significant increase in ovarian or prostate cancer risks for ATM variant carriers.
While management is personalized, many guidelines suggest starting annual breast MRIs by age 30-35 and pancreatic surveillance by age 50 in those with a family history.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References
1. Jiao Y et al. Cancer risks for ATM variant heterozygotes. Genet Med. 2026 Apr 28. doi: undefined. PMID: 42052916.
2. ACMG Clinical Practice Resource. Management of individuals with heterozygous germline pathogenic variants in ATM. Genet Med. 2025 Jan.
3. NCCN Guidelines. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ATM variant carriers face higher risks for breast and pancreatic cancers, with female cumulative breast cancer risk reaching 40% by age 80....
5 months ago
A breakthrough study evaluated H5N1 transmission efficiency across mammalian isolates. Researchers discovered that human-derived D1.1 harboring the PB2 D701N mutation spread efficiently in ferrets, unlike strains carrying PB2 E627K. This finding highlights critical genetic markers for zoonotic surveillance.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
